Objective: Human mutations in the DNA repair genes, Xeroderma pigmentosum (XP)-C and XPA result in hearing loss, which has fueled the hypothesis that there is a significant demand for these genes in protecting cochlear genetic material. Therefore, we quantified the level of XPC and XPA mRNA in the mammalian cochlea.
INTRODUCTION
Xeroderma pigmentosum (XP) is a rare autosomal recessive disease characterized by severe sensitivity of the skin and eyes to sunlight and a 1000-fold increase in sunlight-induced melanomas and cutaneous basal and squamous cell carcinomas (Rapin et al. 2000) . These XP phenotypes result from loss of function mutations in any of the eight genes, termed XPA-G and V. Their gene products regulate the multienzymatic process called nucleotide excision repair (NER), which is the primary molecular pathway for repairing bulky helix-distorting sunlight-induced DNA lesions, such as cyclobutane pyrimidine dimmers and (6 -4) photoproducts (Sugasawa 2008) . Twenty to 30% of patients with XP worldwide belong to a subgroup called XP-neurologic disease that occurs from mutations in the XPD, XPC, or XPA genes (Reardon et al. 1997; Rapin et al. 2000) . In addition to the typical XP phenotypes, these patients exhibit neuronal loss that results in brain atrophy and hearing loss (Robbins et al. 1991) . However, hearing loss may occur in the absence of brain atrophy, which is frequent among patients with XP (Kenyon et al. 1985; Robbin et al. 1991; Oh et al. 2006) . Audiologic assessments have revealed that the hearing loss is localized to the cochlea (Kenyon et al. 1985; Robbins et al. 1991) . The sunlight-induced skin cancers among patients with XP-neurologic disease is consistent with the fact that XP gene products are directly responsible for removing ultraviolet (UV) DNA lesions from the genome. However, brain atrophy and cochlear hearing loss are less obvious, because both the brain and cochlea are shielded from light. Therefore, in addition to repairing UV DNA lesions, the genes (XPD, XPC, and XPA) that underlie XP neurologic disease may harbor other cell survival activities.
The XPD gene product is a 5Ј 3 3Ј helicase that serves as a vital subunit of the general transcription factor, TFIIH (Lehmann 2001; Guthrie 2009 ). XPD maintains the stability of the TFIIH complex during transcription initiation and promoter escape (Lehmann 2001 ). In addition, its helicase activity is needed to unwind DNA around sites of UV lesions to facilitate the docking of DNA repair factors such as XPA during NER (Evans et al. 1997; Winkler et al. 2000) . Therefore, in addition to sunlight-induced DNA repair, XPD plays a role in transcriptional regulation. A loss of function mutation in the XPD gene is expected to manifest as brain atrophy and cochlear hearing loss through faulty transcriptional events coupled with poor DNA repair. However, beyond DNA repair, XPC and XPA have no other known cellular function (Guthrie 2008b ). The XPC gene product scans transcriptionally inactive (silent genes) regions of the genome and localizes chemical or physical aberrations to the normal Watson-Crick structure of DNA. Once XPC identifies the lesion, it initiates NER (Sugasawa et al. 1998) . Although XPC may initially identify a DNA lesion, NER only proceeds after the XPA gene product verifies that the lesion is cytotoxic (Riedl et al. 2003) . This DNA damage verification role of XPA is required for at least two genetically distinct sub-divisions of the NER pathway that operates on transcriptionally active and inactive regions of the genome (Sugasawa et al. 1998) .
XPC and XPA have evolved across phylogeny to protect the genome from UV-induced DNA lesions (Thoma & Vasquez 2003) . However, recent research has revealed that they also exhibit specificity for a broad range of endogenous and exogenous DNA lesions (Riedl et al. 2003; Thoma & Vasquez 2003; Brooks 2007) . Research on the molecular basis of XP neurologic disease have revealed that both XPC and XPA are involved in repairing various types of oxidative DNA lesions (Brooks et al. 2000; Kuraoka et al. 2000; Kassam et al. 2007 ). Indeed, cells from patients with XPC and XPA mutations reveal increased levels of oxidative DNA lesions (Reardon et al. 1997) . The high oxygen metabolism of the brain makes it particularly susceptible to oxidative DNA damage in an XP mutant background, which explains the comorbidity with skin cancers (Kuraoka et al. 2000; Brooks 2007) . Unlike the brain, the molecular basis of cochlear hearing loss has remained unresolved.
We are interested in the role of XP genes in the cochlea because they may help us understand the hypervulnerability of the cochlea to oxidative stressors, such as cisplatin, aminoglycosides, and acoustic over-exposure. A mechanistic understanding of the hypervulnerability of the cochlea to oxidative stressors is a prerequisite to the development of targeted therapeutic strategies. Our previous experiments revealed the existence and distribution of posttranslational products from XP genes in the cochlea for the first time (Guthrie 2008c (Guthrie , 2009 . In additionally, we demonstrated that these posttranslational products are expressed at high levels in the cochlear neurosensory epithelia. These findings are important because recent research has revealed that the cochlea experiences high levels of oxidative stress under normal conditions (Takumida & Anniko 2001; Bánfi et al. 2004; García-Berrocal et al. 2007; Tiede et al. 2007 ); therefore, high expression levels of XP genes would be needed for protection. However, if XP genes are busy with endogenous protection then the cochlea would be unprotected from exogenous oxidative stressors, which provides a basis to interpret cochlear hypervulnerability to oxidative stressors. This study contributes to this line of thinking by providing quantitative evidence through real-time quantitative reverse-transcription polymerase chain reaction to support a high basal demand for XPC and XPA gene products in the cochlea. In additionally, this study supports previous studies by revealing the localization of XPC and XPA gene products in the cochlea through immunohistochemistry.
MATERIALS AND METHODS

Animals and Tissue Preparation
The animals used in this experiment have been described previously (Guthrie et al. 2008) . Briefly, 30 female Fischer344 CDF rats were acquired from Charles River Laboratories, Malvern, PA. The animals were housed at 23 Ϯ 2°C on a 12-hr light/dark cycle and allowed free access to food and water. After the animals acclimated to the rat facility, 15 were sacrificed with a lethal dose of pentobarbital (100 mg/kg, i.p.) and decapitated. The heads were rapidly skinned and the skull resected to allow removal of the brain and access to the osseous labyrinth. Cochlear tissues were dissected immediately from the osseous labyrinth in ice-cold phosphate-buffered saline (pH 7.4) under a stereomicroscope and flash frozen on a dry-ice aluminum block then stored at Ϫ80°C in a monophasic lysis reagent (TRIzol; Invitrogen, Carlsbad, CA). Kidney tissues were also harvested in a similar manner for use as a control organ. All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh, Pittsburgh, PA. The committee ensured that all protocols were consistent with the United States Department of Agriculture and NIH guidelines for the ethical treatment of animals and that all attempts were made to minimize both animal use and suffering.
RNA Purification
Frozen tissues (50 to 100 mg) were homogenized in 1 mL of monophasic lysis reagent. The homogenate was centrifuged after adding chloroform (0.2 mL) to separate the RNA phase from the DNA phase. Isopropyl alcohol (0.25 mL) was used to precipitate RNA that was rinsed with 75% ethanol and solubilized in diethyl pyrocarbonate treated double-distilled water. To remove DNA contamination, the RNA was treated with DNase I (Ambion Inc., Austin, TX) according to the manufacturer's protocol.
Reverse Transcription
Reverse transcription produced complementary DNA (cDNA) from DNA-free RNA. The reverse transcription reaction included 10 L of 10ϫ polymerase chain reaction (PCR) Taq Gold Buffer II (Amplified Biosystems Inc., Foster City, CA), 30 L of 25 mM MgCl 2 , 4 mL of 25 mM of each dNTP, 5 mL of 100 M of random primer (GIBCO BRL, Gaithersburgh, MD), 40 units of RNasin (Applied Biosystems, Inc., Foster City, CA), 250 units of Super-Script-II (GIBCO), and 200 ng of total apo-RNA. The reaction was incubated for 10 mins at 25°C, 30 mins at 48°C, and 5 min at 95°C in a 9600 thermocycler (Applied Biosystems, Inc.).
Real-Time Quantification
Real-time quantification was accomplished with SYBR Green chemistry. The reaction consisted of 5 mL of 10ϫ SYBR green PCR buffer (Applied Biosystems, Inc.), 6 mL of 25 mM MgCl 2 , 4 mL of each dNTPs (blended with 2.5 mM dATP, dGTP and dCTP, and 5 mM dUTP), 2.5 mL of specific gene primers (5 M), 0.5 units of AmpErase UNG, 1.25 units of AmpliTaq Gold, and 5 mL of cDNA in a final volume of 50 L. The rubric for the thermocycling was 2 min at 50°C, 12 mins at 95°C, 40 cycles at 95°C for 15 secs, and 1 min at 60°C in an ABI PRISM 7700 sequence Detection system (Applied Biosystems, Inc.). The gene-specific primers for XPC, XPA, and 18S rRNA (internal control gene) were reported previously (Guthrie et al. 2008 ).
Analysis
The ABI Prism 7700 Sequence Detector Software (Amplified Biosystems, Inc.) was used to measure the net fluorescent spectra of the thermal cycler continuously during PCR amplification. Changes in the emission spectra (⌬R n ) were calculated as,
is the SYBR Green fluorescent signal at any given time after the start of PCR and (R n Ϫ ) is baseline fluorescence (ROX; 6-carboxy-X-rhodamine) before the PCR reaction. ROX does not participate in the PCR amplification; therefore, it provides an internal reference to normalize the fluorescent signal that results from the SBR Green-dsDNA complex. The ⌬R n as a function of PCR cycle number or ⌬R n -cycle function was derived in real time during the PCR. The cycle number at which the fluorescence signal crossed the midlinear portion of the ⌬R n -cycle function is the cycle threshold denoted, C T (Schmittgen et al. 2000) . For statistical and computational analyses, the C T was converted to 2 ϪCT or 2 Ϫ⌬⌬CT (Schmittgen & Livak 2008) . The maximum 2 ϪCT for a particular gene was determined by monitoring C T levels for the gene over 22 days (maximum historic expression). Therefore, the percent expression for any gene was relative to its maximum historic expression under the current experimental conditions. To determine fold change in cochlear gene expression relative to the kidney, the 2 Ϫ⌬⌬CT method was used ( 
For example, the fold change for the cochlear XPA target gene relative to that of the kidney was quantified as follows:
The rat endogenous 18S rRNA (internal control) is used to normalize C T across organs (Guthrie et al. 2008) . To determine fold change in cochlear gene expression relative to another cochlear gene, the 2 Ϫ⌬⌬CT method was used (Schmittgen et al. 2000; Schmittgen & Livak 2008) , where
For example, the fold change for the cochlear XPA target gene relative to the cochlear XPC gene was quantified as follows:
Differences in mRNA expression were examined with repeated measures analysis of variance (ANOVA) or t test.
Immunohistochemistry
The immunohistochemical procedure has been described previously (Guthrie 2008b ). Briefly, 15 rats received intraperitoneal administration of 100 mg of pentobarbital per kilogram of body weight. After a negative response to a paw pinch, the animals were transcardially perfused with phosphate-buffered saline then periodate-lysine-paraformaldehyde fixative. The heads were removed, skinned, and postfixed for 24 hrs at room temperature. They were then decalcified in 10% formic acid, trimmed, and paraffin embedded. These embedded specimens were then sectioned at 8 m with a rotary microtome and mounted on subbed slides. The sections were deparaffinized in xylene and a graded series of ethanol then hydrated. They were then exposed to 30% hydrogen peroxide for 10 mins then heat treated for 20 mins at 90 to 98°C. The sections were then pretreated with a blocking solution of normal goat or horse serum for 1 hr at room temperature. The primary antibodies anti-XPC and anti-XPA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) have been characterized previously (Guthrie et al. 2008; Guthrie 2008b Guthrie , 2009 ). The sections were treated with the antibodies at a concentration of 1:200 for 24 hrs at room temperature. For negative controls, the antibodies were omitted (Guthrie et al. 2008; Guthrie 2008b) . After treatment with the antibody, the sections were incubated with biotinylated secondary goat or rabbit antibodies for 1 hr at room temperature and reacted with preformed avidin-biotinylated enzyme complex. The reaction product was then used to oxidize 3,3Јdiaminobenzidine tetrahydrochloride, which served as chromogen. The sections were then dehydrated and cover-slipped.
RESULTS
XP DNA repair activity in the kidney is among the highest of all the major organs such as brain, heart, lung, spleen, and muscle (Gospodivov et al. 2003) . Therefore, the kinetics and magnitude of XP mRNA expression from the cochlea were compared with that of the kidney on postnatal day (p) 83, 97, and 101. These postnatal days correspond to survival times from a previous study (Guthrie et al. 2008) and are arbitrary to this study. They provide a convenient means of tracking gene expression beyond one time point. Both the kidney and cochlea are composed of several types of cells; therefore, expression refers to the pooled mRNA expression of cells/tissues in the organs. Such pooled expression provides a profile that is specific to each organ and allows for monitoring the kinetics of each gene. Figure 1 is an organ profile of the level and pattern of XPA and XPC gene expression from the kidney and cochlea. The level of expression is shown relative to the maximum expression derived for each organ under the current experimental conditions. In the kidney, XPA gene expression ranged from 42 to 92% of its maximum expression level and a repeated measures ANOVA revealed significant differences in the level of expression between different time points (F[2,8] Gospodivov et al. 2003) .
The cochlea revealed high levels of XP gene expression, similar to the kidney. Cochlear XPA gene expression ranged from 45 to 95% of its maximum expression level and a repeated measures ANOVA revealed significant differences in the level of expression between different time points (F[2,8] ϭ 20.938, p Ͻ 0.05). For instance, follow-up paired samples t test revealed a significant difference between p97 and p101 (t[4] ϭ Ϫ6.178, p Ͻ 0.01). However, there were no significant differences between p83 and p97 (t[4] ϭ 4.322, p Ͼ 0.05) and p83 and p101 (t[4] ϭ Ϫ1.222, p Ͼ 0.05). In additionally, XPC expression ranged from 42 to 69% of its maximum expression level and a repeated measures ANOVA revealed no significant differences in the level of expression between different time points (F[2,8] ϭ 2.686, p Ͼ 0.05). The expression level of XPA from both organs (kidney and cochlea) was closer to saturation (maximum level) than XPC. This suggests that there is a greater basal demand for XPA over XPC.
The pattern of gene expression from each organ is illustrated in Figure 1 . In the kidney, both XPC and XPA showed a similar pattern of expression. For instance, a graded (downward) expression pattern was observed for both genes at serial time points. In the cochlea, both XPC and XPA showed a similar pattern of expression. But unlike the kidney, the cochlear pattern of expression revealed an alternating morphology, characterized as high expression followed by low expression and again by high expression. Therefore, the expression kinetics is organ specific. The combined results reveal that, although XPC and XPA revealed similar kinetics, there is a greater demand for XPA in both kidney and cochlea.
The results in Figure 2 reveal that XP gene expression is higher in the cochlea than in the kidney. For instance, cochlear XPA expression may be equal to or threefold greater than that of the kidney. Interestingly, when cochlear XPA is expressed at 45% of its maximum capacity on p97, it is equal to that of the kidney which is expressing XPA at 77% of its maximum capacity. In additionally, when the kidney is expressing XPA at 92% of its maximum capacity on p83, the cochlea is expressing XPA at 86% (equal to the kidney) of its maximum capacity. Cochlear XPC expression may be three-to sixfolds greater than that of the kidney. Interestingly, when cochlear XPC is expressed at only 42% of its maximum capacity on p97, it is threefold greater than XPC expression in the kidney which is expressed at 70% of its maximum capacity. In additionally, when the kidney is expressing XPC at 78% of its maximum capacity on p83, the cochlea is expressing XPC at 63% of its maximum capacity which is fourfold greater than the kidney. Figure 3 shows the high expression level of XPA. For instance, in the cochlea XPA may be up to 160-fold higher than XPC, which further illustrates a high basal demand for XPA.
The immunohistochemical staining pattern of XP polypeptides over time, under normal conditions, is consistent. However, several previous experiments have revealed prominent changes in the staining pattern of XP polypeptides in the cochlea under ototoxic stress (Guthrie et al. 2008; Guthrie 2008c Guthrie , 2009 . Figures 4 to 7 provides representative photomicrographs of XP immunostaining for the three postnatal days (p83, p97, and p101). Unlike the quantitative nature and high resolution of quantitative reverse-transcription PCR, changes in XPC and XPA are less obvious with immunostaining under normal conditions. Figure 4 reveals that spiral ganglion cells are XP immunopositive and the staining is predominantly cytoplasmic. This cytoplasmic compartmentalization is consistent with translational events but indicates demobilization of the polypeptides (Guthrie et al. 2008 ). However, this cytoplasmic pattern of expression becomes primarily nuclear after genomic stress from the mutagen, cisplatin (Guthrie et al. 2008) . A nuclear pattern of expression of XP polypeptides indicates mobilization due to damaged DNA (Rademakers et al. 2003; Moné et al. 2004; Politi et al. 2005; Wu et al. 2007) . Figure 5 reveals that hair cells and supporting cells of the cochlear neurosensory epithelium are XP immunopositive and the expression is predominantly nuclear with residual cytoplasmic staining. This pattern of expression is consistent with or without genomic stress from the mutagen, cisplatin, and indicates persistent mobilization of XP polypeptides (Guthrie 2008c) . Fibrocytes of the spiral limbus and lateral wall constitute a significant portion of the cells in the cochlea. It is known that fibrocytes and their progenitors are proficient at mobilizing genomic defenses (Brammer et al. 2004) . Figure 6 reveals that cochlear fibrocytes from different tissues (spiral limbus and spiral ligament) are XP immunopositive and the expression is predominantly diffused in the cytoplasm with residual nuclear staining. This diffused cytoplasmic pattern of expression changes to prominent reaction products in the nucleus after genomic stress from the mutagen, cisplatin (Guthrie 2009 ). Figure 7 reveals that several kidney cells are XP immunopositive and the expression is predominantly nuclear with residual cytoplasmic staining. This kidney pattern of expression is consistent with its high intrinsic level of genomic stress that underlies its high susceptibility to exogenous reactive oxygen specie (ROS) stressors (Dmitrieva et al. 2005; Guthrie 2008c) . Table 1 provides a summary of the immunohistochemical findings.
DISCUSSION
The diagnostic criterion for XP-neurologic disease is brain atrophy and cochlear hearing loss (Rapin et al. 2000; Brooks 2007) . Although genomic stress from high oxidative metabolism compels the need for XP genes in the brain, the basis of cochlear hearing loss has remained unresolved. It is possible that similar to the brain, the cochlea is experiencing genomic stress from high oxidative metabolism. Indeed, the high metabolic activity of the cochlea promotes high ROS (Kopke et al. 1999; García-Berrocal et al. 2007) . For instance, the balance between reduced-nicotinamide adenine dinucleotide coenzyme (NADH) and oxidized-flavoproteins (Fp) have revealed significant levels of oxidative redox activity in the cochlea (Tiede et al. 2007) . A prominent source of ROS in the cochlea is based on the activity of NADPH oxidase (NOX)-3. NOX-3 enzymes are single-electron transporters whose primary role is the production of ROS (Bedard & Krause 2007) . In the cochlea, NOX-3 mRNA is expressed 50 to 870 times higher than other organs in the body (Bánfi et al. 2004 ). In additionally, there are several sources of reactive nitrogen species (RNS) production in the cochlea. For instance, nitric oxide (NO) has been directly localized among cochlear cells and isoforms of NO-producing enzymes (NO synthase I, II, and II) are abundant in the cochlea (Takumida & Anniko 2001) . Antioxidants are generally required to combat ROS-/RNS-mediated damage to biomolecules. However, endogenous cochlear antioxidants have been measured at levels lower than other organs (El Barbary et al. 1993 ). For instance, the level of cytosolic antioxidants such as glutathione, glutathione-S-transferase, glutathione reductase, selenium-dependent glutathione peroxidase, and selenium-independent glutathione peroxidase are several folds lower in the cochlea compared with other organs (Lautermann et al. 1997) . Therefore, high production of ROS/RNS coupled with low levels of cytosolic antioxidants suggest that the cochlea is experiencing persistent genomic stress that would require high levels of genome defense molecules to maintain genome integrity and cell survival (Guthrie 2008c) .
XP gene products are important for defending the genome against ROS (Brooks et al. 2000; Brooks 2007 ). Our experimental results showed that cochlear XP gene expression may be as high as 95% of maximum expression capacity, suggesting that under normal conditions XP genes operate close to maximum expression levels. Human mutations in XP genes are known to result in cochlear hearing loss, which implies that XP gene products may be vital genome defense molecules in the cochlea (Kenyon et al. 1985; Robbins et al. 1991) . Furthermore, cochlear XP gene expression may be up-to sixfold greater than that of the kidney, which is particularly significant because XP DNA repair activity in the kidney is among the highest of all the major organs. XP DNA repair operates on genetically active (used) and inactive (unused) regions of the genome. Removal of lesions among genetically active regions is faster and more efficient than genetically inactive regions (Balajee & Bohr 2000) . This difference is based on the notion that the defense of actively transcribed genes has greater priority than inactive genes (Guthrie 2008b) . XPA plays a critical role in protecting both active and inactive genes, whereas XPC only protects inactive genes (Thoma & Vasquez 2003; Sugasawa 2008) . Our data revealed that the expression level of XPA from both kidney and cochlea was closer to saturation (maximum levels) than XPC. This suggests that there is a greater demand for XPA over XPC. In additionally, in the cochlea, XPA could be up to 160-fold greater than XPC. This high expression may reflect the role of XPA in protecting the total genome. High levels of either XPA or Fig. 6 . Fibrocytes is the spiral limbus and lateral wall are immunopositive for XPA and XPC polypeptides. Fibrocytes constitute a significant proportion of cochlear cells and are known to be proficient at mobilizing genomic defenses. Panels A (XPA) and B (XPC) show immunopositive staining in the spiral limbus, and panels C (XPA) and D (XPC) show immunopositive staining in the lateral wall. The staining is predominantly diffused in the cytoplasm with residual nuclear staining. Panel E reveals that omitting the antibody during the immunohistochemical procedure results in negative staining. Scale bars in panels A and B ϭ 10 m and those of panels C-E ϭ 50 m. IC, interdental cells; FC, fibrocytes; OC, osteoclasts; Stv, stria vascularis. Fig. 7 . Several types of kidney cells are immunopositive for XPA and XPC polypepetides. Panel A reveals that omitting the antibody during the immunohistochemical procedure results in negative staining. Panel B shows immunostaining for the XPA polypeptide while panel C shows immunostaining for the XPC polypeptide. Both polypeptides were predominantly localized in the nucleus with residual cytoplasmic staining. G, glumerulus; us, urinary space; TE, tubular epithelium cells; P, podocytes; s, simple squamous epithelial cells. Scale bar (10 m) in panel C also applies to panels A and B.
XPC suggest that the cochlea is experiencing persistent genomic stress (possibly from endogenous ROS) that obligates XP genome defenses.
Genome defense research coupled with cancer biology has demonstrated that XP factors are not only important for maintaining genome integrity from endogenous ROS but they are also implicated in cell survival from exogenous mutagens (Thoma & Vasquez 2003; Guthrie et al. 2008) . For instance, cancer cells that are resistant to cisplatin (an inorganic mutagen) are proficient at up-regulating XP mRNA levels as a function of treatment (States & Reed 1996; Weaver et al. 2005) . Our current data reveal that the normal (nonmalignant) cochlea expresses high levels of XP mRNA. However, it is known from both human and animal research that cochlear damage is a frequent side effect of cisplatin chemotherapy (van den Berg et al. 2006; Rybak et al. 2007 ). Cisplatin chemotherapy results in DNA damage among the various cochlear epithelia yet the neurosensory epithelium is significantly more susceptible to degeneration than the nonsensory epithelia (Hoistad et al. 1998; Cheng et al. 2001; van Ruijven et al. 2005; Thomas et al. 2006 ). This suggests that there is a difference in XP DNA repair capacity between cochlear epithelia.
Recent experiments have revealed that under normal conditions the cochlear neurosensory epithelium expresses XP translational products at high levels relative to the nonsensory epithelia (Guthrie 2008c (Guthrie , 2009 ). In additionally, under conditions of genomic stress from cisplatin, the neurosensory epithelium is unable to mobilize XP translational products beyond basal demand, whereas the nonsensory epithelia that are much more resistant to cisplatin actively mobilized XP translational products beyond basal demand. These observations have led to the hypothesis of basal demand interference at which basal demand for high levels of genome defenses precludes a substantive response to exogenous stress (Guthrie 2008c ). This line of thinking is particularly significant, because it may help to elucidate the intrinsic vulnerability of the cochlea to exogenous auditory stressors, such as acoustic-overexposure and ototoxic xenobiotics (Guthrie 2008a ). Both these exogenous auditory stressors perpetuate additional ROS production in the cochlea (Kopke et al. 1999; Rybak et al. 2007 ). If cochlear XP defenses are operating close to saturation under normal conditions (due to high endogenous ROS), then a limited reservoir would be available for mobilization under conditions of exogenous stress. Therefore, the current data supplement previous experiments by providing a basis to interpret and further investigate the intrinsic susceptibility of the cochlea to exogenous auditory stressors. Implicit in the data is the notion that turning down cochlear levels of oxidative stress under normal conditions might relieve XP DNA repair enzymes to defend the cochlea under stressful conditions. Therefore, future clinical strategies aimed at protecting the cochlea from oxidative stress might benefit from freeing up endogenous defense enzymes before exposure to an ROS inducing condition. The combined line of research for the first time implicates genomic stress and XP DNA repair factors as mechanisms underlying cochlear pathophysiology.
In conclusion, this work revealed that XP genes are expressed at high levels in the cochlea under normal conditions, which suggest a high demand for XP genome defense in the cochlea and provides a basis to further explore why mutations in XP genes result in cochlear hearing loss. In additionally, the data may be audiologically/otologically important because it supports the hypothesis that basal demand interference may underlie the intrinsic susceptibility of the cochlea to exogenous ROS inducing stressors. Therefore, future therapeutic strategies may yield clinical success by reducing endogenous stress, so that endogenous defenses are free to manage stress from exogenous sources. 
